Form 4: Checkpoint Therapeutics Director Disposes of All Shares Following Merger Agreement

Checkpoint Therapeutics, Inc. Director and 10% owner Michael S. Weiss has disposed of all his common stock holdings, totaling 187,007 shares, as part of a merger agreement for $4.10 cash per share plus a contingent value right.

Summary

• Michael S. Weiss, a Director and 10% owner of Checkpoint Therapeutics, Inc. (CKPT), reported transactions related to his beneficial ownership.
• On May 28, 2025, Mr. Weiss acquired 12,195 shares of common stock at $0.00, bringing his indirect beneficial ownership to 137,007 shares, which included restricted shares vesting over time and held by Hawkins BioVentures, LLC.
• On May 29, 2025, he acquired an additional 50,000 shares of common stock at $1.29 per share, increasing his direct beneficial ownership to 187,007 shares.
• On May 30, 2025, Mr. Weiss disposed of all 187,007 shares of common stock, resulting in zero beneficial ownership, in connection with an offer made pursuant to the Agreement and Plan of Merger.
• The merger consideration for the disposed shares was $4.10 per share in cash, net to the holder, plus one contractual contingent value right (CVR) per share.
• Each CVR represents the right to receive a payment ranging from $0.20 to $0.70, contingent upon certain milestone payments related to the regulatory approval for cosibelimab in the European Union.
• The CVR milestone must be achieved within 36 months after cosibelimab receives a positive validation outcome by the European Medicines Agency.

Sentiment

Score: 7

Explanation: The sentiment is generally positive as the transaction represents the successful completion of a merger for shareholders, providing immediate cash and potential upside via CVRs. The CVR introduces some uncertainty, but the core transaction is a positive exit.

Positives

• The disposition is part of a merger agreement, indicating a successful acquisition for shareholders at a pre-determined price.
• Shareholders receive a fixed cash payment of $4.10 per share, providing immediate liquidity and certainty.
• The inclusion of a Contingent Value Right (CVR) offers potential additional upside of $0.20 to $0.70 per share based on future regulatory milestones for cosibelimab in the EU.

Negatives

• The disposition of all shares by a director and 10% owner signifies the end of their direct equity stake in Checkpoint Therapeutics, Inc.
• The CVR component introduces uncertainty regarding the final per-share value, as the additional payment is contingent on future regulatory approval and timing.

Risks

• The value of the Contingent Value Right (CVR) is not guaranteed and depends entirely on the achievement of specific regulatory milestones for cosibelimab in the European Union.
• There is a risk that the European regulatory approval for cosibelimab may not be obtained, or may be delayed beyond the 36-month timeframe, potentially resulting in no CVR payment.
• The CVR payment range of $0.20 to $0.70 indicates variability, and the actual payment could be at the lower end or zero if milestones are not fully met.

Future Outlook

The future outlook for former Checkpoint Therapeutics shareholders includes potential additional payments via Contingent Value Rights (CVRs) ranging from $0.20 to $0.70 per share. These payments are contingent upon the successful regulatory approval of cosibelimab in the European Union, with a milestone achievement deadline of 36 months following a positive validation outcome by the European Medicines Agency.

Industry Context

This Form 4 filing reflects the finalization of an acquisition in the biotechnology and pharmaceutical sector, a common occurrence as larger companies seek to integrate promising drug candidates or technologies. The use of Contingent Value Rights (CVRs) is a growing trend in biotech mergers, allowing acquirers to mitigate risk by tying a portion of the acquisition price to the successful achievement of future clinical or regulatory milestones, particularly for assets still in development or awaiting approval.

Related Party Transactions

• The shares acquired on May 28, 2025, were restricted shares vesting over various time periods, subject to Mr. Weiss's continued service on the board, and were held indirectly by Hawkins BioVentures, LLC, of which Mr. Weiss is the sole member.

Stakeholder Impact

• Shareholders: Receive $4.10 cash per share and one CVR per share, providing liquidity and potential future upside.

Next Steps

• Achievement of regulatory approval for cosibelimab in the European Union.
• Potential payment of CVRs ranging from $0.20 to $0.70 per share upon milestone achievement within 36 months of EMA positive validation.

Key Dates

Keywords

Checkpoint Therapeutics, CKPT, Michael S. Weiss, Form 4, Insider Transaction, Share Disposition, Merger Agreement, Contingent Value Right, CVR, Cosibelimab, European Union Regulatory Approval, Biotechnology, Pharmaceuticals